BioPorto A/S (THOXF)
USD 0.29
(0.0%)
USD 0.29
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -61.17 Million DKK | 22.74% |
| 2022 | -77.87 Million DKK | -19.34% |
| 2021 | -65.25 Million DKK | -2.62% |
| 2020 | -63.59 Million DKK | 14.41% |
| 2019 | -74.29 Million DKK | -77.83% |
| 2018 | -41.78 Million DKK | -14.49% |
| 2017 | -36.49 Million DKK | -45.7% |
| 2016 | -25.04 Million DKK | -96.31% |
| 2015 | -12.75 Million DKK | 16.37% |
| 2014 | -15.25 Million DKK | 22.96% |
| 2013 | -19.8 Million DKK | -42.77% |
| 2012 | -13.87 Million DKK | -7.87% |
| 2011 | -12.85 Million DKK | 4.12% |
| 2010 | -13.41 Million DKK | 16.27% |
| 2009 | -16.01 Million DKK | -14.04% |
| 2008 | -14.04 Million DKK | 0.0% |
| 2007 | -14.04 Million DKK | -195.81% |
| 2006 | 14.65 Million DKK | 2.12% |
| 2005 | 14.35 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -17.87 Million DKK | -21.57% |
| 2024 Q1 | -14.7 Million DKK | 1.36% |
| 2023 Q2 | -17.85 Million DKK | -5.46% |
| 2023 Q4 | -14.9 Million DKK | -60.85% |
| 2023 Q3 | -9.26 Million DKK | 48.1% |
| 2023 Q1 | -16.92 Million DKK | 32.32% |
| 2023 FY | -60.16 Million DKK | 22.74% |
| 2022 Q4 | -25.01 Million DKK | -36.99% |
| 2022 FY | -77.87 Million DKK | -19.34% |
| 2022 Q1 | -18.03 Million DKK | -2.91% |
| 2022 Q2 | -20.13 Million DKK | -11.67% |
| 2022 Q3 | -18.25 Million DKK | 9.34% |
| 2021 Q4 | -17.52 Million DKK | -28.53% |
| 2021 FY | -65.25 Million DKK | -2.62% |
| 2021 Q1 | -16.84 Million DKK | -10.08% |
| 2021 Q2 | -14.51 Million DKK | 13.82% |
| 2021 Q3 | -13.63 Million DKK | 6.08% |
| 2020 Q3 | -17.7 Million DKK | -6.42% |
| 2020 Q1 | -16.41 Million DKK | 1.28% |
| 2020 FY | -63.59 Million DKK | 14.41% |
| 2020 Q2 | -16.63 Million DKK | -1.35% |
| 2020 Q4 | -15.3 Million DKK | 13.58% |
| 2019 Q2 | -16.52 Million DKK | 3.61% |
| 2019 Q4 | -16.62 Million DKK | 30.71% |
| 2019 Q3 | -23.99 Million DKK | -45.2% |
| 2019 FY | -74.29 Million DKK | -77.83% |
| 2019 Q1 | -17.14 Million DKK | -121.73% |
| 2018 Q4 | -7.73 Million DKK | 32.95% |
| 2018 FY | -41.78 Million DKK | -14.49% |
| 2018 Q1 | -12.55 Million DKK | -53.95% |
| 2018 Q2 | -9.96 Million DKK | 20.65% |
| 2018 Q3 | -11.53 Million DKK | -15.79% |
| 2017 Q1 | -9.28 Million DKK | -94.98% |
| 2017 Q4 | -8.15 Million DKK | 23.54% |
| 2017 Q3 | -10.66 Million DKK | -27.12% |
| 2017 FY | -36.49 Million DKK | -45.7% |
| 2017 Q2 | -8.39 Million DKK | 9.66% |
| 2016 Q4 | -4.76 Million DKK | 33.16% |
| 2016 FY | -25.04 Million DKK | -96.31% |
| 2016 Q1 | -5.44 Million DKK | -149.18% |
| 2016 Q2 | -7.71 Million DKK | -41.58% |
| 2016 Q3 | -7.12 Million DKK | 7.6% |
| 2015 Q1 | -4.42 Million DKK | -53.93% |
| 2015 Q3 | -2.1 Million DKK | 47.8% |
| 2015 Q4 | -2.18 Million DKK | -3.7% |
| 2015 Q2 | -4.03 Million DKK | 8.79% |
| 2015 FY | -12.75 Million DKK | 16.37% |
| 2014 Q1 | -3.62 Million DKK | 23.75% |
| 2014 FY | -15.25 Million DKK | 22.96% |
| 2014 Q3 | -3.07 Million DKK | 45.9% |
| 2014 Q4 | -2.87 Million DKK | 6.44% |
| 2014 Q2 | -5.68 Million DKK | -56.79% |
| 2013 Q1 | -5.09 Million DKK | -29.72% |
| 2013 FY | -19.8 Million DKK | -42.77% |
| 2013 Q3 | -5.44 Million DKK | -20.73% |
| 2013 Q4 | -4.75 Million DKK | 12.71% |
| 2013 Q2 | -4.51 Million DKK | 11.46% |
| 2012 Q4 | -3.92 Million DKK | -46.97% |
| 2012 Q2 | -3.58 Million DKK | 2.66% |
| 2012 Q1 | -3.68 Million DKK | -1.4% |
| 2012 Q3 | -2.67 Million DKK | 25.51% |
| 2012 FY | -13.87 Million DKK | -7.87% |
| 2011 Q1 | -1.27 Million DKK | 66.68% |
| 2011 Q3 | -1.63 Million DKK | 67.52% |
| 2011 Q4 | -3.63 Million DKK | -121.99% |
| 2011 FY | -12.85 Million DKK | 4.12% |
| 2011 Q2 | -5.04 Million DKK | -295.92% |
| 2010 Q2 | -2.97 Million DKK | 13.99% |
| 2010 Q4 | -3.82 Million DKK | -21.11% |
| 2010 Q3 | -3.15 Million DKK | -6.05% |
| 2010 FY | -13.41 Million DKK | 16.27% |
| 2010 Q1 | -3.45 Million DKK | 12.72% |
| 2009 Q3 | -3.52 Million DKK | 27.36% |
| 2009 Q1 | -3.66 Million DKK | 0.0% |
| 2009 FY | -16.01 Million DKK | -14.04% |
| 2009 Q4 | -3.96 Million DKK | -12.3% |
| 2009 Q2 | -4.85 Million DKK | -32.48% |
| 2008 FY | -14.04 Million DKK | 0.0% |
| 2007 FY | -14.04 Million DKK | -195.81% |
| 2006 FY | 14.65 Million DKK | 2.12% |
| 2005 FY | 14.35 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | -4825.282% |
| Arrayit Corporation | -3.62 Million USD | -1588.66% |
| Atlantic International Corp. | -5.73 Million USD | -967.107% |
| Biocept, Inc. | -31.98 Million USD | -91.264% |
| Bioqual, Inc. | -19.63 Thousand USD | -311398.116% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | -7822.377% |
| DermTech, Inc. | -103.73 Million USD | 41.033% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 102.46% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | -193.678% |
| iMD Companies, Inc. | -175.44 Thousand USD | -34766.569% |
| IDenta Corp. | -1499.00 USD | -4080753.903% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 2281.598% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 158208.038% |
| InVitro International | -25.33 Thousand USD | -241314.42% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | -758.916% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -105165.694% |
| Medical Imaging Corp. | -819.48 Thousand USD | -7364.734% |
| NovelStem International Corp. | -3.52 Million USD | -1634.983% |
| Optigenex Inc. | 1.39 Million USD | 4498.221% |
| PharmChem, Inc. | 973.14 Thousand USD | 6385.998% |
| Proteome Sciences plc | -1.62 Million USD | -3673.72% |
| Response Genetics, Inc | -21.37 Million USD | -186.158% |
| Rennova Health, Inc. | -1.4 Million USD | -4239.874% |
| RushNet, Inc. | -684.7 Thousand USD | -8834.066% |
| ScreenPro Security Inc. | -2.59 Million USD | -2259.641% |
| Stella Diagnostics Inc. | -11.42 Million USD | -435.331% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | -689.646% |
| Todos Medical Ltd. | -9.74 Million USD | -527.534% |